



ASX RELEASE

29 April 2011

Tissue Therapies despatches Rights Issue Prospectus today

Tissue Therapies Limited (**Tissue Therapies**) despatched the Prospectus for its non-renounceable rights issue to raise approximately \$9.36 million to shareholders today.

The Prospectus was lodged with ASIC and ASX Limited on 15 April 2011 on the same day that the placement to sophisticated and professional investors raising approximately \$5.75 million was announced.

The Offer closes at 5.00pm (AEST) on 19 May 2011.

Steven Mercer
Chief Executive Officer

Further information please contact

Dr Steven Mercer
CEO, Tissue Therapies Limited
Telephone: 07 3839 9938
Email: s.mercer@tissuetherapies.com

About Tissue Therapies Limited

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue repair, cell culture and other applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a technology developed by cell biology, tissue engineering and protein engineering experts at the Institute for Health and Biomedical Innovation (IHBI) at the Queensland University of Technology (QUT) for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, cell based therapies and other cell culture uses.

Based on its VitroGro® technology, Tissue Therapies is developing more effective treatments for acute and chronic wound healing applications including chronic skin ulcers and burns.

Tissue Therapies is also proceeding with the development of other commercial applications for VitroGro® and other technologies for the treatment of psoriasis, scar prevention and treatment and potential treatments for various cancers including those of the breast, colon and prostate.

VitroGro® also provides a fundamental, transforming technology for completely defined cell culture reagents (ie. containing no purified animal or human proteins) to sustain and enhance the growth of live cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

More information: www.tissuetherapies.com